Cipla's Avenue Therapeutics gets USFDAs Complete Response Letter for IV tramadol

The drug major's subsidiary, Avenue Therapeutics Inc. has received a second Complete Response Letter (CRL) from the US drug regulator regarding its New Drug Application (NDA) seeking approval for IV tramadol.

Avenue Therapeutics Inc is the company focused on the development of intravenous (IV) tramadol for the US market. The CRL stated that the delayed and unpredictable onset of analgesia with IV tramadol does not support its benefit as a monotherapy to treat patients in acute pain, and there is insufficient information to support that IV tramadol in combination with other analgesics is safe and effective for the intended patient population. The Food and Drug Administration (FDA) did not identify any Chemistry, Manufacturing and Controls (CMC) issues in this CRL.

Avenue Therapeutics disagreed with the FDA's interpretation of the data in the NDA and intends to continue to pursue regulatory approval for IV tramadol.

On a consolidated basis, Cipla's net profit surged 71.5% to Rs 415.51 crore on 6.6% rise in net sales to Rs 4,584.88 crore in Q4 FY21 over Q4 FY20.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

Shares of Cipla lost 0.43% to Rs 972 on BSE. The stock traded in the range of Rs 970.40 to Rs 978.65 so far.

Powered by Capital Market - Live News